Optonol Overview
Optonol's flagship product, Ex-Press, is a miniature surgical implant used to lower intra-ocular pressure in patients with glaucoma. Optonol was founded as a spin-off of Jerusalem-based stent developer Medinol Ltd. Optonol was acquired by Alcon in December 2009. A year later, Alcon was acquired by Novartis.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Alcon buys Israeli glaucoma treatment co Optonol
Israeli glaucoma treatment company Optonol Ltd. has been acquired by US eye care company Alcon in a deal potentially worth hundreds of millions of dollars. Optonol will receive an initial cash payment of $150 million for its Ex-Press mini-glaucoma shunt family of products. Milestone payments could earn the company hundreds of millions of dollars. Optonol was founded in 1996 and has raised $30 million in funding. The acquisition is expected to close by the end of the first quarter of 2010.
Acquisition
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30M |
| Last funding | $20M |
| Stage | Acquired |
| Rounds | 2 |
| Investors | 5 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | optonol.com |
Locations
Neve Ilan, Israel
Photos & Videos
No files yet
